Astellas sees US Xtandi sales reaching $400m this fiscal year
This article was originally published in Scrip
Executive Summary
Astellas has cut its guidance for both sales and profit for the fiscal year ending 31 March, despite a strong start in the US for its prostate cancer drug Xtandi (enzalutamide; licensed from Medivation).